Quest Diagnostics Inc. (DGX)

From the record

Quest Diagnostics Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Quest Diagnostics Inc.'s 10 filed years say what it did: revenue went from $1 million in fiscal 2016 to $13 million in fiscal 2025, up 33% a year; it rose in 6 of 9 years; the deepest fall was 80% from fiscal 2019 to fiscal 2021; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Quest Diagnostics Inc.'s diluted share count shrank about 1.4% a year, and dividends and buybacks returned about 42% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 40 sales (38 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Quest Diagnostics Inc. earned about 14 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned less than nothing, about minus 45 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 56 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).

From the record

Quest Diagnostics Inc.'s standing among 24 graded names in its industry family: revenue of $13 million in fiscal 2025 ranks in the bottom 24% by size; a net margin of 7630.8% ranks in the top 2%; revenue growth of 9.1% a year over the last 3 filed years ranks in the bottom 41% (its annual reports).

From the record

Quest Diagnostics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Davis, J. E. (CEO and President, as filed), filing under that title since 2022-11-03, 4 years (bottom 44% of its family); the 19 officers and directors filing in the last fifteen months have been on the record a median of 6.7 years (top 30%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 19 people in charge now (top 34%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Quest Diagnostics Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $420 million against debt of $5.2 billion leaves -29.3% of its assets as net cash, bottom 13% of its family; cash from operations less capital spending is 10453.8% of revenue (top 2%); a gross margin of -56592.3% (bottom 3%) (its annual report).

From the record

Quest Diagnostics Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 9.1% a year over the last three filed years against 33% over all 10, slowing (bottom 20% of its family); the newest year grew -48% (bottom 2%); capital spending grew 9.3% a year (top 31%) (its annual reports). Quest Diagnostics Inc. reported 2 lines of business in fiscal 2025: Diagnostic Information Services Business at $11 billion, All Other at $250 million. 1 of 2 grew in the latest filed year, and the largest line is 98% of revenue (its annual report).

From the record

Quest Diagnostics Inc.'s newest year against its own record: revenue of $13 million in fiscal 2025 came in 67.1% below the $40 million its prior three years' pace pointed to (bottom 3% of its family); net income of $992 million against a prior three-year average of $890 million (bottom 38%); a net margin of more than its whole revenue against more than its whole revenue before (top 12%) (its annual reports).